Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kingsoft Cloud Holdings Limited (KC) vs Mesoblast Limited (MESO) Price & Performance

Kingsoft Cloud Holdings LimitedTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Kingsoft Cloud Holdings Limited vs Mesoblast Limited — how do they compare? Kingsoft Cloud Holdings Limited trades at $10.02 (market cap $3.01B), while Mesoblast Limited trades at $16.08 (market cap $2.17B). The key difference: Kingsoft Cloud Holdings Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals.

KCMESO
Market Cap
$3.01B$2.17B
Sector
TechnologyTechnology
52-Week High
$18.21$20.96
52-Week Low
$8.58$12.88
Enterprise Value
$3.32B$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kingsoft Cloud Holdings Limited

Kingsoft Cloud (KC) trades at $10.04, up 5.24% today, showing strong momentum despite a bearish technical signal. The company reported Q1 2026 revenue growth of 37% year-over-year, driven by AI cloud demand, though profitability remains challenged with a -9.39% net margin. Analyst sentiment is positive with 70% buy ratings, citing potential from AI expansion and trade easing between the U.S. and China.

KC presents a growth opportunity in cloud and AI services with strong revenue acceleration, but investors face risks from persistent losses, high capital expenditure, and competitive pressures. The stock's outlook hinges on margin improvement from AI investments and sustained demand, making it suitable for growth-oriented investors tolerant of near-term volatility.

Mesoblast Limited

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

Returns comparison

Trailing returns across standard periods

About Kingsoft Cloud Holdings Limited

Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.

Read more on KC

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO